NASDAQ:CTMX

CytomX Therapeutics Competitors

$6.74
-0.98 (-12.69 %)
(As of 04/12/2021 12:00 AM ET)
Add
Compare
Today's Range
$6.73
Now: $6.74
$7.77
50-Day Range
$7.40
MA: $8.06
$8.92
52-Week Range
$6.25
Now: $6.74
$15.44
Volume1.51 million shs
Average Volume1.01 million shs
Market Capitalization$436.64 million
P/E RatioN/A
Dividend YieldN/A
Beta0.74

Competitors

CytomX Therapeutics (NASDAQ:CTMX) Vs. AMRX, CYTK, ZNTL, IRWD, HRMY, and AUPH

Should you be buying CTMX stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to CytomX Therapeutics, including Amneal Pharmaceuticals (AMRX), Cytokinetics (CYTK), Zentalis Pharmaceuticals (ZNTL), Ironwood Pharmaceuticals (IRWD), Harmony Biosciences (HRMY), and Aurinia Pharmaceuticals (AUPH).

Amneal Pharmaceuticals (NYSE:AMRX) and CytomX Therapeutics (NASDAQ:CTMX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, risk and profitability.

Profitability

This table compares Amneal Pharmaceuticals and CytomX Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Amneal Pharmaceuticals3.30%42.02%3.82%
CytomX Therapeutics-58.13%-94.20%-13.79%

Volatility & Risk

Amneal Pharmaceuticals has a beta of 1.27, meaning that its stock price is 27% more volatile than the S&P 500. Comparatively, CytomX Therapeutics has a beta of 0.74, meaning that its stock price is 26% less volatile than the S&P 500.

Valuation and Earnings

This table compares Amneal Pharmaceuticals and CytomX Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amneal Pharmaceuticals$1.63 billion1.06$-361,920,000.00$0.2721.37
CytomX Therapeutics$57.49 million7.60$-102,240,000.00($2.26)-2.98

CytomX Therapeutics has lower revenue, but higher earnings than Amneal Pharmaceuticals. CytomX Therapeutics is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

33.5% of Amneal Pharmaceuticals shares are held by institutional investors. Comparatively, 77.9% of CytomX Therapeutics shares are held by institutional investors. 26.3% of Amneal Pharmaceuticals shares are held by insiders. Comparatively, 5.8% of CytomX Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings and price targets for Amneal Pharmaceuticals and CytomX Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Amneal Pharmaceuticals02502.71
CytomX Therapeutics02502.71

Amneal Pharmaceuticals currently has a consensus target price of $6.2143, suggesting a potential upside of 7.70%. CytomX Therapeutics has a consensus target price of $12.0714, suggesting a potential upside of 79.10%. Given CytomX Therapeutics' higher probable upside, analysts clearly believe CytomX Therapeutics is more favorable than Amneal Pharmaceuticals.

Summary

Amneal Pharmaceuticals beats CytomX Therapeutics on 8 of the 12 factors compared between the two stocks.

Cytokinetics (NASDAQ:CYTK) and CytomX Therapeutics (NASDAQ:CTMX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, risk and profitability.

Volatility & Risk

Cytokinetics has a beta of 1.45, meaning that its stock price is 45% more volatile than the S&P 500. Comparatively, CytomX Therapeutics has a beta of 0.74, meaning that its stock price is 26% less volatile than the S&P 500.

Valuation and Earnings

This table compares Cytokinetics and CytomX Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cytokinetics$26.87 million63.50$-121,690,000.00($2.11)-11.30
CytomX Therapeutics$57.49 million7.60$-102,240,000.00($2.26)-2.98

CytomX Therapeutics has higher revenue and earnings than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than CytomX Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and price targets for Cytokinetics and CytomX Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cytokinetics011002.91
CytomX Therapeutics02502.71

Cytokinetics currently has a consensus target price of $33.6364, suggesting a potential upside of 41.03%. CytomX Therapeutics has a consensus target price of $12.0714, suggesting a potential upside of 79.10%. Given CytomX Therapeutics' higher probable upside, analysts clearly believe CytomX Therapeutics is more favorable than Cytokinetics.

Insider & Institutional Ownership

97.1% of Cytokinetics shares are held by institutional investors. Comparatively, 77.9% of CytomX Therapeutics shares are held by institutional investors. 6.4% of Cytokinetics shares are held by insiders. Comparatively, 5.8% of CytomX Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Cytokinetics and CytomX Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cytokinetics-209.88%-3,065.14%-36.39%
CytomX Therapeutics-58.13%-94.20%-13.79%

CytomX Therapeutics (NASDAQ:CTMX) and Zentalis Pharmaceuticals (NASDAQ:ZNTL) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, earnings, risk and valuation.

Valuation & Earnings

This table compares CytomX Therapeutics and Zentalis Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CytomX Therapeutics$57.49 million7.60$-102,240,000.00($2.26)-2.98
Zentalis PharmaceuticalsN/AN/AN/AN/AN/A

Zentalis Pharmaceuticals has lower revenue, but higher earnings than CytomX Therapeutics.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for CytomX Therapeutics and Zentalis Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
CytomX Therapeutics02502.71
Zentalis Pharmaceuticals00703.00

CytomX Therapeutics presently has a consensus price target of $12.0714, suggesting a potential upside of 79.10%. Zentalis Pharmaceuticals has a consensus price target of $56.4286, suggesting a potential upside of 39.61%. Given CytomX Therapeutics' higher possible upside, equities research analysts plainly believe CytomX Therapeutics is more favorable than Zentalis Pharmaceuticals.

Insider & Institutional Ownership

77.9% of CytomX Therapeutics shares are held by institutional investors. Comparatively, 67.1% of Zentalis Pharmaceuticals shares are held by institutional investors. 5.8% of CytomX Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares CytomX Therapeutics and Zentalis Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CytomX Therapeutics-58.13%-94.20%-13.79%
Zentalis PharmaceuticalsN/AN/AN/A

Summary

Zentalis Pharmaceuticals beats CytomX Therapeutics on 5 of the 9 factors compared between the two stocks.

CytomX Therapeutics (NASDAQ:CTMX) and Ironwood Pharmaceuticals (NASDAQ:IRWD) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, earnings, risk and valuation.

Volatility and Risk

CytomX Therapeutics has a beta of 0.74, indicating that its share price is 26% less volatile than the S&P 500. Comparatively, Ironwood Pharmaceuticals has a beta of 1.46, indicating that its share price is 46% more volatile than the S&P 500.

Valuation & Earnings

This table compares CytomX Therapeutics and Ironwood Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CytomX Therapeutics$57.49 million7.60$-102,240,000.00($2.26)-2.98
Ironwood Pharmaceuticals$428.41 million3.82$21.50 million$0.5518.47

Ironwood Pharmaceuticals has higher revenue and earnings than CytomX Therapeutics. CytomX Therapeutics is trading at a lower price-to-earnings ratio than Ironwood Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for CytomX Therapeutics and Ironwood Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
CytomX Therapeutics02502.71
Ironwood Pharmaceuticals04102.20

CytomX Therapeutics presently has a consensus price target of $12.0714, suggesting a potential upside of 79.10%. Ironwood Pharmaceuticals has a consensus price target of $11.40, suggesting a potential upside of 12.20%. Given CytomX Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe CytomX Therapeutics is more favorable than Ironwood Pharmaceuticals.

Insider & Institutional Ownership

77.9% of CytomX Therapeutics shares are held by institutional investors. 5.8% of CytomX Therapeutics shares are held by company insiders. Comparatively, 2.4% of Ironwood Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares CytomX Therapeutics and Ironwood Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CytomX Therapeutics-58.13%-94.20%-13.79%
Ironwood Pharmaceuticals27.77%-240.80%27.05%

CytomX Therapeutics (NASDAQ:CTMX) and Harmony Biosciences (NASDAQ:HRMY) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, earnings, risk and valuation.

Valuation & Earnings

This table compares CytomX Therapeutics and Harmony Biosciences' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CytomX Therapeutics$57.49 million7.60$-102,240,000.00($2.26)-2.98
Harmony BiosciencesN/AN/AN/AN/AN/A

Harmony Biosciences has lower revenue, but higher earnings than CytomX Therapeutics.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for CytomX Therapeutics and Harmony Biosciences, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
CytomX Therapeutics02502.71
Harmony Biosciences00303.00

CytomX Therapeutics presently has a consensus price target of $12.0714, suggesting a potential upside of 79.10%. Harmony Biosciences has a consensus price target of $51.6667, suggesting a potential upside of 79.90%. Given Harmony Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Harmony Biosciences is more favorable than CytomX Therapeutics.

Insider & Institutional Ownership

77.9% of CytomX Therapeutics shares are held by institutional investors. Comparatively, 50.2% of Harmony Biosciences shares are held by institutional investors. 5.8% of CytomX Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares CytomX Therapeutics and Harmony Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CytomX Therapeutics-58.13%-94.20%-13.79%
Harmony BiosciencesN/AN/AN/A

Summary

Harmony Biosciences beats CytomX Therapeutics on 5 of the 9 factors compared between the two stocks.

CytomX Therapeutics (NASDAQ:CTMX) and Aurinia Pharmaceuticals (NASDAQ:AUPH) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, earnings, risk and valuation.

Volatility and Risk

CytomX Therapeutics has a beta of 0.74, indicating that its share price is 26% less volatile than the S&P 500. Comparatively, Aurinia Pharmaceuticals has a beta of 0.87, indicating that its share price is 13% less volatile than the S&P 500.

Valuation & Earnings

This table compares CytomX Therapeutics and Aurinia Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CytomX Therapeutics$57.49 million7.60$-102,240,000.00($2.26)-2.98
Aurinia Pharmaceuticals$320,000.005,034.31$-123,850,000.00($0.89)-14.20

CytomX Therapeutics has higher revenue and earnings than Aurinia Pharmaceuticals. Aurinia Pharmaceuticals is trading at a lower price-to-earnings ratio than CytomX Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for CytomX Therapeutics and Aurinia Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
CytomX Therapeutics02502.71
Aurinia Pharmaceuticals01702.88

CytomX Therapeutics presently has a consensus price target of $12.0714, suggesting a potential upside of 79.10%. Aurinia Pharmaceuticals has a consensus price target of $28.50, suggesting a potential upside of 125.47%. Given Aurinia Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Aurinia Pharmaceuticals is more favorable than CytomX Therapeutics.

Insider & Institutional Ownership

77.9% of CytomX Therapeutics shares are held by institutional investors. Comparatively, 51.2% of Aurinia Pharmaceuticals shares are held by institutional investors. 5.8% of CytomX Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares CytomX Therapeutics and Aurinia Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CytomX Therapeutics-58.13%-94.20%-13.79%
Aurinia Pharmaceuticals-173,992.23%-36.98%-31.06%


CytomX Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Amneal Pharmaceuticals logo
AMRX
Amneal Pharmaceuticals
1.6$5.77-3.3%$1.73 billion$1.63 billion14.07Decrease in Short Interest
News Coverage
Cytokinetics logo
CYTK
Cytokinetics
1.7$23.85-1.3%$1.71 billion$26.87 million-12.49Insider Selling
News Coverage
Zentalis Pharmaceuticals logo
ZNTL
Zentalis Pharmaceuticals
1.8$40.42-7.4%$1.66 billionN/A0.00Analyst Report
News Coverage
Gap Down
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.8$10.16-0.3%$1.64 billion$428.41 million14.72
Harmony Biosciences logo
HRMY
Harmony Biosciences
1.4$28.72-1.4%$1.63 billionN/A0.00
Aurinia Pharmaceuticals logo
AUPH
Aurinia Pharmaceuticals
1.8$12.64-1.3%$1.61 billion$320,000.00-8.60Analyst Report
ADC Therapeutics logo
ADCT
ADC Therapeutics
1.7$22.76-5.4%$1.57 billion$2.34 million-9.64
Myovant Sciences logo
MYOV
Myovant Sciences
1.3$17.18-5.6%$1.56 billionN/A-6.11Increase in Short Interest
News Coverage
Prelude Therapeutics logo
PRLD
Prelude Therapeutics
1.4$32.70-7.8%$1.52 billionN/A0.00
uniQure logo
QURE
uniQure
1.7$33.14-1.8%$1.49 billion$7.28 million-8.79
Heron Therapeutics logo
HRTX
Heron Therapeutics
1.7$16.29-1.9%$1.49 billion$145.97 million-6.60
Applied Molecular Transport logo
AMTI
Applied Molecular Transport
2.0$42.12-16.2%$1.48 billionN/A0.00
Travere Therapeutics logo
TVTX
Travere Therapeutics
1.3$24.52-4.4%$1.48 billion$175.34 million-14.42Analyst Report
News Coverage
Supernus Pharmaceuticals logo
SUPN
Supernus Pharmaceuticals
1.4$27.97-1.2%$1.48 billion$392.76 million11.61
Generation Bio logo
GBIO
Generation Bio
1.8$26.06-4.4%$1.47 billionN/A0.00Increase in Short Interest
Cassava Sciences logo
SAVA
Cassava Sciences
0.9$35.96-15.6%$1.43 billionN/A-149.83
ImmunoGen logo
IMGN
ImmunoGen
1.5$7.18-5.3%$1.43 billion$82.27 million-17.51
Kronos Bio logo
KRON
Kronos Bio
1.7$25.41-7.4%$1.42 billionN/A0.00Insider Selling
High Trading Volume
Unusual Options Activity
News Coverage
Aclaris Therapeutics logo
ACRS
Aclaris Therapeutics
0.8$27.46-5.5%$1.42 billion$4.23 million-20.34Increase in Short Interest
Endo International logo
ENDP
Endo International
1.3$6.17-0.5%$1.42 billion$2.91 billion-9.07News Coverage
ATBPD
Antibe Therapeutics
0.1$3.66-6.0%$1.42 billion$7.51 million-6.10
Cara Therapeutics logo
CARA
Cara Therapeutics
1.6$28.36-2.9%$1.41 billion$19.89 million-13.38
COMPASS Pathways logo
CMPS
COMPASS Pathways
1.5$38.19-6.3%$1.40 billionN/A0.00
Zealand Pharma A/S logo
ZEAL
Zealand Pharma A/S
1.2$32.09-2.2%$1.39 billion$6.20 million-14.07
PMV Pharmaceuticals logo
PMVP
PMV Pharmaceuticals
1.4$31.08-7.1%$1.39 billionN/A0.00Increase in Short Interest
Keros Therapeutics logo
KROS
Keros Therapeutics
1.6$58.69-2.5%$1.37 billionN/A0.00Increase in Short Interest
Arcutis Biotherapeutics logo
ARQT
Arcutis Biotherapeutics
1.6$27.10-1.8%$1.36 billionN/A-2.94
Theravance Biopharma logo
TBPH
Theravance Biopharma
1.6$20.55-1.9%$1.34 billion$73.41 million-4.34
Zymeworks logo
ZYME
Zymeworks
1.8$28.46-8.9%$1.31 billion$29.54 million-7.55
Shattuck Labs logo
STTK
Shattuck Labs
1.4$30.75-8.2%$1.28 billionN/A0.00Increase in Short Interest
News Coverage
OLMA
Olema Pharmaceuticals
1.6$31.73-3.5%$1.27 billionN/A0.00Increase in Short Interest
Ocular Therapeutix logo
OCUL
Ocular Therapeutix
1.6$16.20-1.9%$1.23 billion$4.23 million-9.05
Stoke Therapeutics logo
STOK
Stoke Therapeutics
1.4$33.04-4.0%$1.21 billionN/A-18.36
Repare Therapeutics logo
RPTX
Repare Therapeutics
1.6$32.46-5.2%$1.20 billionN/A0.00
Phathom Pharmaceuticals logo
PHAT
Phathom Pharmaceuticals
1.8$38.00-1.3%$1.19 billionN/A-2.72
Innoviva logo
INVA
Innoviva
1.4$11.67-0.3%$1.18 billion$261.02 million5.95
Praxis Precision Medicines logo
PRAX
Praxis Precision Medicines
1.7$29.95-1.4%$1.16 billionN/A0.00Increase in Short Interest
Lockup Expiration
Avid Bioservices logo
CDMO
Avid Bioservices
1.7$18.93-2.4%$1.15 billion$59.70 million-189.30
Protagonist Therapeutics logo
PTGX
Protagonist Therapeutics
1.5$26.22-1.4%$1.15 billion$230,000.00-12.20
Y-mAbs Therapeutics logo
YMAB
Y-mAbs Therapeutics
1.6$26.33-0.2%$1.15 billionN/A-8.87Increase in Short Interest
News Coverage
Gap Down
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.7$10.07-0.0%$1.14 billion$35.22 million-7.35
NKTX
Nkarta
1.8$34.01-5.1%$1.12 billionN/A0.00Increase in Short Interest
Kiniksa Pharmaceuticals logo
KNSA
Kiniksa Pharmaceuticals
1.7$16.15-9.5%$1.10 billionN/A-6.81News Coverage
Pliant Therapeutics logo
PLRX
Pliant Therapeutics
1.9$30.70-10.4%$1.10 billion$57.05 million0.00
Mersana Therapeutics logo
MRSN
Mersana Therapeutics
1.5$15.86-0.3%$1.10 billion$42.12 million-11.75
Zogenix logo
ZGNX
Zogenix
1.7$18.93-1.8%$1.06 billion$3.65 million-1.99Analyst Upgrade
News Coverage
Omeros logo
OMER
Omeros
1.4$16.93-7.7%$1.05 billion$111.81 million-7.11
Constellation Pharmaceuticals logo
CNST
Constellation Pharmaceuticals
1.2$21.84-3.0%$1.05 billionN/A-8.06
MannKind logo
MNKD
MannKind
1.4$4.18-1.4%$1.04 billion$63.04 million-19.90Increase in Short Interest
Syndax Pharmaceuticals logo
SNDX
Syndax Pharmaceuticals
1.6$21.27-4.2%$1.03 billion$1.52 million-11.31Increase in Short Interest
This page was last updated on 4/13/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.